Skip to main
SION

SION Stock Forecast & Price Target

SION Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 20%
Hold 20%
Sell 10%
Strong Sell 0%

Bulls say

Sionna Therapeutics is a promising biopharmaceutical company with a strong cash position and promising pipeline. The completion of patient enrollment for the Phase IIa PreciSION study in summer 2026 and potential positive results from this study, as well as the ongoing Phase I dual combo study, could greatly benefit the company and the CF community. With positive feedback from experts and plans for its own combination treatment, Sionna has the potential to revolutionize CF treatment and improve the lives of patients.

Bears say

Sionna Therapeutics is a clinical-stage biopharmaceutical company with a negative outlook, as there are concerns about the predictiveness of their preclinical data and the potential impact of subtle differences between their CFHBE work and that of their competitor, VRTX. Additionally, their stock target price has been raised to $55 from $44, yet their dual NBD1 combination revenues are only risk-adjusted at 40%. While SION has potential, its success is dependent on their ability to stabilize NBD1, which has historically been a difficult target to achieve with small molecule drugs.

SION has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 10% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sionna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sionna Therapeutics Inc (SION) Forecast

Analysts have given SION a Buy based on their latest research and market trends.

According to 10 analysts, SION has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sionna Therapeutics Inc (SION)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.